Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib

Novartis Pharmaceuticals103 enrolled

Overview

This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray. The survey assessed the knowledge of HCPs prescribing Piqray in relation to the management of hyperglycemia in patients treated with Piqray.

Study Type

OBSERVATIONAL

Enrollment

103

Conditions

Breast Cancer

Interventions

Piqray Prescriber's/HCP guide for hyperglycemiaOTHER

oncologists/healthcare professionals (HCPs) prescribing Piqray in the EU/EEA were provided with the Piqray Prescriber's/HCP Guide for hyperglycemia (educational material). The educational material aimed to provide oncologists/HCPs prescribing Piqray with additional measures/guidance prior to, and during treatment with Piqray for the identification and management of hyperglycemia.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Had prescribed Piqray to at least 1 locally advanced or MBC patient within 6 months prior to completing the survey. * Provided permission to share their anonymized responses in aggregate with EMA or NCAs, if requested. Exclusion Criteria: HCPs who are direct employees of Novartis, the EMA (or any other regulatory bodies), or ICON.

Locations (1)

Novartis Investigative Site

Basel, Switzerland

Outcomes

Primary Outcomes

assess HCPs' knowledge and understanding of the key information included in the Piqray Prescriber's/HCP Guide for hyperglycemia

The primary endpoint was a composite endpoint based on the percentages of HCPs with correct responses to all questions included in the composite regarding the below information: * Risk of hyperglycemia and its potential risk factors * Signs and symptoms of hyperglycemia * Recommendations for monitoring for hyperglycemia prior to, and during, treatment with Piqray * Recommendations for managing hyperglycemia during treatment with Piqray. Specifically, the primary endpoint was a weighted composite knowledge score aggregated across the following survey questions: 4A, 5A-C, 6, 8A-C, 10, and 12-15. It was calculated as the number of all correctly answered questions divided by the number of all answered questions (i.e. questions that were answered either correct and not correct - unanswered questions are excluded).

Time frame: Throughout study completion, an average of 1 year

Secondary Outcomes

Assess HCPs' reported levels of receipt, and reading, of the Piqray Prescriber's/HCP Guide for hyperglycemia

Assessed as the percentages of HCPs who report receipt and reading of the same (survey questions 1, 2).

Time frame: Throughout study completion, an average of 1 year

Assess HCPs' knowledge levels for each survey question regarding knowledge of, and management of, hyperglycemia

Assessed as the percentages of HCPs with correct responses to each question (individual responses to survey questions 4-15).

Time frame: Throughout study completion, an average of 1 year

Assess the primary source from which HCPs learned about the messages included in the Piqray Prescriber's/HCP Guide for hyperglycemia

Assessed as the percentages of HCPs who report using each of the possible sources as the primary source they used (survey question 3).

Time frame: Throughout study completion, an average of 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.